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AbstrACt
Introduction Type 2 diabetes mellitus (T2DM) remains 
one of the most common chronic diseases of adulthood 
which creates high degrees of morbidity and mortality 
worldwide. The incidence of T2DM continues to rise and 
recently, mHealth interventions have been increasingly 
used in the prevention, monitoring and management of 
T2DM. The aim of this study is to systematically review 
the published evidence on cost and cost-effectiveness 
of mHealth interventions for T2DM, as well as assess the 
quality of reporting of the evidence.
Methods and analysis A comprehensive review of 
PubMed, EMBASE, Science Direct and Web of Science of 
articles published until January 2019 will be conducted. 
Included studies will be partial or full economic evaluations 
which provide cost or cost-effectiveness results for 
mHealth interventions targeting individuals diagnosed 
with, or at risk of, T2DM. The quality of reporting evidence 
will be assessed using the Consolidated Health Economic 
Evaluation Reporting Standards (CHEERS) checklist. 
Results will be presented using a flowchart following the 
Preferred Reporting Items for Systematic Review and 
Meta-Analysis Protocols (PRISMA-P) guidelines. Graphical 
and tabulated representations of the results will be created 
for both descriptive and numerical results. The cost and 
cost-effectiveness values will be presented as reported by 
the original studies as well as converted into international 
dollars to allow comparability. As we are predicting 
heterogenous results, we will conduct a narrative and 
interpretive analysis of the data.
Ethics and dissemination No formal approval or review 
of ethics is required for this systematic review as it will 
involve the collection and analysis of secondary data. 
This protocol follows the current PRISMA-P guidelines. 
The review will provide information on the cost and cost-
effectiveness of mHealth interventions targeting T2DM. 
These results will be disseminated through publication and 
submission to conferences for presentations and posters.
PrOsPErO registration number CRD42019123476
IntrOduCtIOn
description of the condition
Type 2 diabetes mellitus (T2DM) is a chronic 
disease where the patient becomes progres-
sively resistant to insulin causing a tendency to 
develop high blood sugars and symptomatic 
cardiovascular disease.1 In poorly controlled 
patients, diabetes can cause a substantial 
number of morbidity and mortality due to 
cardiovascular, ocular and nephrogenic 
complications.2 The prevalence of diabetes 
is increasing with 425 million adults thought 
to be living with the condition in 2018, that 
is, around 8.5% of the adult population.1 3 In 
2015, diabetes was the sixth highest cause for 
disability worldwide.4 The loss of productivity 
due to diabetes and its health consequences 
causes an economic burden to patients, 
healthcare providers and country’s economy, 
mounting to 1.8% of the global gross domestic 
product (GDP) and 12% of the global health 
expenditure in 2018.3 5 Moreover, more than 
80% of yearly deaths due to diabetes occur 
in developing countries where the economic 
consequences are greater than in developed 
counterparts.6 
The prevention and management of the 
diabetes consists of lifestyle modifications 
(including weight, exercise and nutritional 
changes) and, if unsuccessful, the pharmaco-
logical control of hyperglycaemia.7 For many 
patients, the diagnosis and management of 
strengths and limitations of this study
 ► This review will address a gap in the literature re-
garding the cost and cost-effectiveness of mHealth 
interventions for individuals with or at risk of type 2 
diabetes mellitus.
 ► The protocol follows the latest Preferred Reporting 
Items for Systematic Review and Meta-Analysis 
Protocols guidelines and we will use a Consolidated 
Health Economic Evaluation Reporting Standards 
checklist to assess the quality of reporting evidence 
by the included studies.
 ► The validity and quality of the results will depend on 
the quality of the identified studies.
 ► The heterogenicity of the identified studies may 
complicate the narrative analysis of the results.
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the condition challenges their lifestyle habits including 
exercise and diet. Therefore, many patients still demon-
strate low willingness to change their unhealthy life-
style habits.8 9 To overcome these barriers, technology 
has demonstrated encouraging potential in supporting 
patients’ behavioural changes by providing an empow-
ering, portable every-day reminder of their diabetes 
management plan.10
description of the intervention
It is estimated that 96.8% of adults worldwide have access 
to a mobile phone, while, 43.4% of individuals are using 
the internet,11 this increases to 94.4% if solely describing 
high-income countries.12 The large growth of wireless 
connection has created a platform for technology-based 
opportunities in healthcare combining patient empower-
ment with the convenience of mobile devices. mHealth 
can be defined as the integration of mobile devices, 
personal digital assistants and other technological wire-
less systems to improve the health of individuals.13 
Importantly, it can help to equilibrate the disparities in 
healthcare access and quality by diminishing barriers for 
patients to access healthcare advice and monitoring.14 The 
use of mHealth has increased exponentially throughout 
the last two decades with early research consisting mostly 
of small pilot studies, while, current research is increas-
ingly structured and evidence based.15 16
diabetes and mHealth
Studies evaluating the clinical effectiveness of mHealth 
interventions targeting diabetes have demonstrated clin-
ical usefulness in the prevention and control of diabetes 
utilising lifestyle modification and blood glucose moni-
toring applications.17–19 A meta-analysis review demon-
strated that there is a statistically significant reduction 
in blood glucose levels among patients using mobile 
phone interventions.20 Additionally, a systematic review 
found that glycaemic control results are amplified when 
two different methods are used in conjunction with one 
another, such as text reminders and blood glucose record 
keeping.21 mHealth interventions have been shown to be 
low cost and cost-effective across medical specialties, such 
as cardiovascular and renal medicine, however, there are 
significant gaps in the economic literature addressing 
mHealth interventions targeted at individuals with or at 
risk of T2DM.14
Why do this review?
mHealth for diabetes shows clinical promise, however, there 
is a lack of cost and cost-effectiveness evidence in regard 
to mHealth interventions. A systematic review evaluating 
the cost and cost-effectiveness of mHealth interventions 
targeting T2DM is required to close a gap in the literature.
Aim
The aim of this study is to systematically review the 
published evidence on the cost and cost-effectiveness of 
mHealth interventions for T2DM.
specific objectives
1. To identify and summarise the cost and cost-effective-
ness evidence for mHealth interventions targeting 
T2DM.
2. To evaluate the quality of reporting of the evidence.
3. To identify the main drivers of the cost and cost-effec-
tiveness results among these interventions.
MEtHOds
types of studies
All partial and full economic evaluation studies presenting 
data for mHealth interventions directed at patients 
diagnosed or at risk of T2DM will be included. Partial 
economic evaluations are defined as evaluations that 
provide the cost of the intervention but do not, however, 
compare the costs with an alternative intervention or to 
the outcomes of the intervention.22 All studies that report 
cost of the intervention, either from provider (eg, design 
and implementation costs), patients (eg, subscription 
fee, cost of changing behaviour) or societal perspectives, 
will be included in the review. Full economic evaluations 
compare the costs of the intervention with one or more 
alternative interventions (ie, comparators) and relate 
these to the outcomes. Full economic evaluations include 
cost-effectiveness analysis (CEA), cost-utility analysis 
(CUA), cost–benefit analysis (CBA), cost-minimisation 
analysis and cost-consequence analysis.22
types of participants
Included mHealth interventions will be targeted at indi-
viduals who are diagnosed with or are at risk of developing 
T2DM due to impaired glucose tolerance. This review will 
include mHealth interventions implemented in both low- 
and middle- and high-income settings.
types of interventions
All mHealth interventions targeting patients at risk of or 
with diagnosed T2DM that involve the use of the internet, 
mobile devices or computer-based interventions will be 
included in the review. We recognise that mHealth is a 
vast subject area and, therefore, we will attempt to cate-
gorise included mHealth interventions into relevant 
subgroups to facilitate comparability.
Outcome measures
The common outcome measures such as incremental 
cost-effectiveness ratios, average cost-effectiveness ratio, 
benefit–cost ratio and unit costs will be extracted from 
the selected studies. We will report outcome measures 
as presented in the original studies and, for comparison, 
we will convert the original values to 2017 international 
dollars using purchasing power parity for the country 
where the study is conducted.
Exclusion criteria
Studies will be excluded from our analysis if they are:
 ► Not published in a peer reviewed journal.
 ► Not available in the English language.
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 ► Not addressing mHealth based interventions.




We will conduct a literature search on the following 
online databases from inception to end of January 2019 
for studies published in English on:
 ► MEDLINE (PubMed).
 ► EMBASE.
 ► Web of Science.
 ► Science Direct.
Other searches
We will additionally review the reference lists of identified 
studies for any further relevant studies.
search strategy
We will use the search strategy with the key words speci-
fied in box 1 for all four online databases. We will modify 
the search strategy to suit all four databases.
data collection and analysis
Selection of studies
Relevant papers will be selected in two steps: in the first 
step, two authors (GR and AH) will independently review 
the titles and abstracts of the studies resulting from the 
above search and, in the second step, the full text of the 
selected papers in the first step will be screened. The 
search will be managed in Endnote X7 to facilitate the 
organisation and management of the selection process. 
Any disagreements among the authors will be discussed 
until an agreement is reached with consultation of 
another experienced author (HH-B). The outline of the 
study selection procedure will be shown in a preferred 
reporting items for systematic review and meta-analysis 
protocol (PRISMA-P) flowchart (figure 1).23 After the 
consensus on the final studies for inclusion, the authors 
will analyse the full publications data extraction.
data extraction
General information and economic features will be 
collected from all the selected studies including date of 
publication, study design, type of intervention (ie, type 
of mHealth), objective of the intervention, duration of 
the intervention, setting of the intervention (ie, based 
on income level and geographical region), platform of 
the intervention and demographics of the participants. 
Furthermore, economic evaluation details such as type 
of analysis (ie, CEA, CUA, CBA and so on), perspective 
of analysis, type of outcome measured, time horizon, 
type of data used (primary, secondary or mixed), type 
of sensitivity analysis and measures of uncertainty will 
be recorded. These data will be recorded and extracted 
using a data extraction tool designed for this purposed 
(online additional file 1) based on existing guidelines 
and other economic evaluation articles.22 24 25
In addition, we will evaluate the main drivers of the costs 
and cost-effectiveness results based on the findings from 
sensitivity analyses conducted by the included studies.
Quality of reporting evidence
We will assess the quality of reporting the economic 
evidence presented in the selected full economic evalu-
ation studies using the Consolidated Health Economic 
Evaluation Reporting Standards (CHEERS) checklist.26 
For partial economic evaluations, we developed a tool 
using the relevant criteria in the CHEERS checklist, some 
modified and the tools used by previous researchers.27 
Two authors (GR and AH) will use these checklists inde-
pendently and any discrepancies will be discussed among 
them until a consensus is reached. If discrepancies 
continue then third author (HH-B) will be involved to 
resolve these. The CHEERS checklist includes 24 items 
which are divided into five subheadings: title and abstract, 
introduction, methods, results and discussion (online 
additional file 2). The checklist for partial economic 
evaluations or costing studies is a 16-item checklist with 
similar subheadings as the CHEERS (online additional 
file 3). The quality of reporting of the included papers 
will be presented using the checklists in both table and 
graph format to ensure a numerical and visual represen-
tation of the quality limitations of the studies.
Patient and public involvement
As this is a protocol for a systematic review, we did not 
have patient or public involvement throughout the 
design, recruitment and conduct of this protocol.
Analysis
Summarising results
Results will be summarised using appropriate tables and 
figures to ensure a complete and objective account of our 
findings. We will include a general summary table quanti-
fying the main characteristics of the included studies such 
as study design (randomised control trial, before-after, 
modelling and so on), type of mHealth intervention, time 
horizon, country income setting and outcome measure 
box 1 search strategy key words
((((((((((m-health) OR ehealth) OR mhealth) OR MeSH) OR mobile health) 
OR telemedicine) OR e-health) OR application) OR app) OR electronic 
health)).
AND (((((((((diabetes) OR Type 2 Diabetes) OR Diabetes Mellitus) OR 
T2DM) OR DM2) OR impaired glucose tolerance) OR insulin resistance) 
OR pre-diabet*) OR impaired fasting tolerance).
AND (((((((((((cost effectiv*) OR cost-effetiv*) OR cost benefit) OR 
cost-benefit) OR cost-utility) OR cost utility) OR cost analysis) OR 
cost-analysis) OR economic evaluation) OR cost*) OR cost outcome)).
AND ((((((((((((((monitor*) OR control*) OR management) OR prevention) 
OR risk reduction) OR lifestyle modification) OR exercis*) OR physical 
fitness) OR bariatric surgery) OR metformin) OR diet) OR weight loss) 
OR food) OR obesity) OR BMI.
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used (refer to online additional file 1). A more detailed 
account of the outcome measures will be presented and 
categorised via mHealth intervention type allowing the 
subdivision and ranking of the cost and cost-effectiveness 
of different mHealth interventions. To facilitate compara-
bility of the results across countries and years, costs will be 
converted to 2017 international dollars using purchasing 
power parity conversion factors for each study setting. To 
evaluate cost-effectiveness, results will also be compared 
against the WHO’s cost-effectiveness threshold,28 as well 
as, an alternative threshold by Woods et al’s,29 using the 
setting’s GDP per capita.
Addressing bias
We will critically analyse the results of our review for 
possible bias. Particularly, we are aware of publication bias; 
often published studies demonstrate positive results and 
research demonstrating negative results may be lacking.30 
Additionally, we will exclude studies that are not available 
in the English language and which are not published in 
a peer-reviewed journal, therefore, we acknowledge the 
bias that this may introduce.
subgroup analysis
If sufficient studies are included, we plan on carrying out 
analysis among subgroups. For example, one stratifica-
tion method will be the subdivision of interventions by 
mHealth category, such as mobile phone applications or 
computer-based interventions. Second, subdividing the 
interventions according to their objective, for example, 
diabetes prevention versus diabetes control, may allow 
a greater generalisability of results. Other potential 
sub-analyses we may include is the evaluation of cost and 
cost-effectiveness results according to the study design 
(eg, randomised control trial, modelling), the coun-
tries’ income level (low, middle or high) or geographical 
region.
dIsCussIOn
Although there is some evidence on the effectiveness 
of mHealth interventions in non-communicable disease 
such as diabetes and cardiology, evidence on cost and 
cost-effectiveness evidence of these interventions is 
limited. To the best of our knowledge, this is the first 
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study that will systematically review the cost and cost-ef-
fectiveness of mHealth interventions targeting T2DM. 
Where sufficient data are available, we will also conduct 
subgroup analyses and explore the main drivers of costs 
and cost-effectiveness results.
The limitations of our study regard the quality and 
the heterogeneity of the selected studies. To address 
these limitations, we will use the CHEERS checklist and 
a modified CHEERS checklist to evaluate the quality of 
the all the included cost-effectiveness and costing studies, 
respectively. We anticipate heterogeneous results and 
predict limited scope for a meta-analysis, therefore, we 
will perform a narrative analysis. To contextualise and 
compare the heterogeneous results, we will convert the 
results into 2017 international dollars. Another possible 
limitation of this study, is its susceptibility to publication 
and small sample biases, which, will be considered when 
interpreting the results.
COnCLusIOn
This systematic review will provide evidence to close a 
significant gap in the literature addressing the costs and 
cost-effectiveness of mHealth interventions targeted at 
T2DM. Conclusions will be based on the results from 
both full and partial economic evaluations. Summarising 
the cost and cost-effectiveness of mHealth interventions 
will provide useful information for policy makers when 
designing and implementing these interventions.
Ethics and dissemination
No formal ethical review or approval is needed as there 
will be no primary collection of data involved in this 
review. The results of this review will be submitted to a 
peer-reviewed journal for publication. The findings will 
also be shared at international conferences. This review 
will address the gap in the literature concentrating on the 
cost and cost-effectiveness of mHealth interventions for 
T2DM. We predict that this information will help to influ-
ence the decision-making surrounding mHealth interven-
tions targeting people at risk of or diagnosed with T2DM.
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